Literature DB >> 8778988

Immunopathogenesis and spectrum of infections in systemic lupus erythematosus.

A G Iliopoulos1, G C Tsokos.   

Abstract

OBJECTIVE: This study reviews the pertinent immunopathologic mechanisms that contribute to increased susceptibility to infection in patients with systemic lupus erythematosus (SLE) and the spectrum of infections in patients with SLE. It assesses the impact on patient care, morbidity, and mortality.
METHODS: The authors performed an extensive search of the literature through MEDLINE, using appropriate keywords and manual search of bibliography cited by retrieved papers.
RESULTS: Infection is a leading cause of morbidity and mortality in SLE and may change the natural course of the disease. Patients with SLE display numerous cellular and humoral abnormalities that are expressed in a heterogeneous pattern and contribute in varying degrees to susceptibility to infectious agents. The use of corticosteroid and immunosuppressive drugs is only partially responsible for the high infection rate in lupus patients. Common as well as opportunistic pathogens are frequently encountered among patients with SLE. The susceptibility that SLE patients exhibit to certain bacteria is now better recognized, and a broadening spectrum of pathogens is being reported. The immunization of patients against influenza and pneumococcus and the administration of prophylactic therapy against Pneumocystis carinii infection in certain patients have recently been proposed.
CONCLUSION: Disease activity and treatment are responsible for the extensive defects of the immune defense system in lupus patients that increase their susceptibility to an extensive range of infections. Infection imposes a serious burden on lupus patients and on the caring physician.

Entities:  

Mesh:

Year:  1996        PMID: 8778988     DOI: 10.1016/s0049-0172(96)80018-7

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  42 in total

1.  Prophylactic use of antibiotics and immunisations in patients with SLE.

Authors:  W R Gilliland; G C Tsokos
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

2.  Estrogen upregulates cyclic AMP response element modulator α expression and downregulates interleukin-2 production by human T lymphocytes.

Authors:  Vaishali R Moulton; Dana R Holcomb; Melissa C Zajdel; George C Tsokos
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 3.  New insights into the pathogenesis of systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; Christina G Katsiari; Yuang-Taung Juang; George C Tsokos
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

4.  Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus.

Authors:  Yuang-Taung Juang; Thomas Rauen; Ying Wang; Kunihiro Ichinose; Konrad Benedyk; Klaus Tenbrock; George C Tsokos
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

5.  A large pseudoaneurysm of the superficial femoral artery in a patient with SLE with Salmonella group D infection.

Authors:  Chih-Wei Liu; Ming-Li Hung; Hsien-Tzung Liao; Chang-Youh Tsai
Journal:  BMJ Case Rep       Date:  2018-03-20

6.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

Review 7.  Progressive disseminated histoplasmosis in systemic lupus erythematosus-an unusual presentation of acute tenosynovitis and a literature review.

Authors:  Sian Yik Lim; Kunut Kijsirichareanchai; Richard Winn
Journal:  Clin Rheumatol       Date:  2012-10-14       Impact factor: 2.980

8.  Superoxide anion production by neutrophils is associated with prevalent clinical manifestations in systemic lupus erythematosus.

Authors:  Celene M O S Alves; Cleni M Marzocchi-Machado; Paulo Louzada-Junior; Ana Elisa C S Azzolini; Ana Cristina M Polizello; Ivan F de Carvalho; Yara M Lucisano-Valim
Journal:  Clin Rheumatol       Date:  2007-10-23       Impact factor: 2.980

Review 9.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

10.  Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.

Authors:  L Georgescu; R K Vakkalanka; K B Elkon; M K Crow
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.